iNtRON identifies Prophage and Jamphage in the Pancreatic cancer related Microbiome
Retrieved on:
Tuesday, May 30, 2023
SON, Survivor, Alkalihalobacillus clausii, IR, Biotechnology, Prevalence, Pancreatic cancer, Bacteriophage, Drug discovery, Survival, Open reading frame, Mode of action, Cancer, STS, Radio spectrum, Research, DSM-IV codes, Colorectal cancer, Acquisition, Parkinson's disease, Patient, Pancreas, Immune system, Intron, Mode, Growth, Bacteria, Mall of America, Recurrence, LTS, Alzheimer's disease, Genome, Vaccine, Pharmaceutical industry, Large intestine, Prophage
BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today the identification of Prophage and (non-) ORF-Jamphage from the microbiome frequently observed in long-term Pancreatic cancer survivors.
Key Points:
- BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today the identification of Prophage and (non-) ORF-Jamphage from the microbiome frequently observed in long-term Pancreatic cancer survivors.
- The ultimate goal is to develop phage-based immunotherapeutics capable of treating a range of immune disorders including cancer.
- The primary focus of the company lies in Colorectal cancer and Pancreatic cancer.
- Alkalihalobacillus clausii has been identified as a representative microbiome, and iNtRON has obtained the strain and confirmed the presence of Prophage and Jamphage through the genomic analysis.